- ongoing, recruitingTherapeutic use (Phase IV)
REDUCE PMR: Rituximab Effect on Decreasing glUcoCorticoid Exposition in newly diagnosed PolyMyalgia Rheumatica
This study looks at whether a medicine called rituximab can help people with newly diagnosed polymyalgia rheumatica reduce or stop taking steroid medication (glucocorticoids) one year after treatment, compared to a dummy treatment.
Netherlands - authorisedTherapeutic exploratory (Phase II)
A randomized, double blind, placebo-controlled, phase II, multicentre trial to explore the efficacy and safety of oral AP1189 tablets administered at the dose 100 mg/day for 12 weeks in patients diagnosed with polymyalgia rheumatica and in remission on glucocorticoid
This study is looking into a new tablet called AP1189 for people with polymyalgia rheumatica (PMR) who are doing well on their current steroid medication. Researchers want to see if this new tablet, taken daily for 12 weeks, is safe and can help patients stay well without steroids.
Denmark - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of Baricitinib as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects with New-Onset Polymyalgia Rheumatica (JAK-SPARE 1)
This study is looking at a new treatment called Olumiant for polymyalgia rheumatica. It aims to see if Olumiant can help people get better and reduce their need for steroid medications, which often have side effects. Researchers are checking how well it works and if it's safe.
Austria · Czechia · Italy - ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR)
This study is testing a new medicine, secukinumab, for polymyalgia rheumatica (PMR). It compares secukinumab with a dummy treatment (placebo) alongside a common steroid medicine to see if it helps reduce symptoms and allows people to use less steroid medicine.
Denmark · Italy · France - recruiting
Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
This study aims to better understand, diagnose, and manage Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR). Researchers are looking at various body markers and using advanced imaging to improve how these conditions are found and treated.
Germany - recruiting
Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)
This study aims to understand Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) better. Researchers are looking for genetic links to these conditions to learn more about how they develop. It includes people with a diagnosis of GCA or PMR, aged 50 or over.
United Kingdom - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A trial of prednisolone in combination with SPI-62 in participants with polymyalgia rheumatica (PMR)
This study is looking at a new medicine called SPI-62, given along with a common medication called prednisolone. It's for people who have polymyalgia rheumatica (PMR), a condition that causes muscle pain and stiffness. The main goal is to see if this new combination is safe.
Germany - active not recruitingPHASE3
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
This study is looking at the long-term safety of a treatment called secukinumab for people with Polymyalgia Rheumatica (PMR). It's for those who have already been in a previous study for secukinumab and had their PMR symptoms come back after stopping treatment.
United States · Argentina · Australia